Investor Presentaiton

SAR-Bombesin in prostate cancer Detection of PSMA-negative prostate cancer SAR-Bombesin was able to locate tumours in PSMA-negative prostate cancers that are not visible with approved PSMA diagnostics -10% of prostate cancer patients do not express PSMA PSMA negative prostate cancer patients will not respond to PSMA imaging or therapy 75-100% of prostate cancer patients express GRPr Diagnosis and treatment of these patients with TCTs targeting GRPr opens new possibilities Significant clinical synergies with existing SAR-bisPSMA program for clinical and development and regulatory affairs 68Ga PSMA-11 CLARITY PHARMACEUTICALS 64CU SAR- Bombesin CLARITY 68Ga PSMA-11 CLARITY PHARMACEUTICALS 64CU SAR- Bombesin 68Ga PSMA-11 (top) images of a PSMA-negative patient with clinical signs of prostate cancer (a rising PSA score of 0.16 ng/mL) and 64Cu SAR-Bombesin PET/CT images of the same patient (bottom) 68Ga PSMA-11 (top) image of a PSMA-negative patient with history of prostate cancer (a rising PSA score of 25 ng/mL) and 64Cu SAR-Bombesin PET/CT image of the same patient (bottom) 18

View entire presentation